体外诊断产品

Search documents
迈克生物:迈小颜仍处于初创阶段
Zheng Quan Ri Bao Zhi Sheng· 2025-08-22 12:13
证券日报网讯 迈克生物8月22日在互动平台回答投资者提问时表示,目前迈小颜仍处于初创阶段,公司 旨在尝试探索生物化学技术与皮肤健康管理的有机结合,公司主业仍聚焦于体外诊断产品的研发、生 产、销售和相关服务。敬请广大投资者谨慎决策,注意投资风险。 (编辑 王雪儿) ...
塞力医疗股价下跌7% 成交额突破14亿元
Sou Hu Cai Jing· 2025-08-20 13:49
Group 1 - The stock price of Saily Medical is reported at 29.20 yuan, down 2.20 yuan from the previous trading day [1] - The opening price was 30.37 yuan, with a highest point of 30.86 yuan and a lowest point of 29.01 yuan [1] - The trading volume for the day was 472,100 hands, with a transaction amount of 1.409 billion yuan [1] Group 2 - Saily Medical operates in the pharmaceutical commercial sector, primarily engaged in the research, development, production, and sales of medical testing centralized services and in vitro diagnostic products [1] - The company's business includes overall solutions for hospital testing departments and the construction of regional testing centers in the medical service field [1] Group 3 - On August 20, during the morning session, Saily Medical experienced a rapid rebound, with a rise of over 2% within 5 minutes, reaching a peak price of 30.10 yuan [1] - Data shows that on that day, the net outflow of main funds was 185 million yuan, accounting for 3.32% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow of main funds was 59.9759 million yuan, representing 1.08% of the circulating market value [1]
亚辉龙股价微涨0.77% 实控人拟减持3%股份
Jin Rong Jie· 2025-08-18 17:02
亚辉龙最新股价报15.63元,较前一交易日上涨0.77%。盘中最高触及15.85元,最低下探15.53元,成交 金额1.28亿元。 该公司属于医疗器械行业,主营业务为体外诊断产品的研发、生产和销售。其产品涵盖免疫诊断、生化 诊断、分子诊断等领域,主要应用于医院检验科、体检中心等医疗机构。 8月18日公司公告显示,控股股东、实际控制人兼董事长胡鹍辉计划减持不超过3%的公司股份,副总经 理兼核心技术人员肖育劲计划减持不超过0.11%的股份。此外,公司为四家全资子公司提供不超过1.15 亿元的担保,目前公司及控股子公司对外担保余额约3.15亿元。 资金流向方面,当日主力资金净流出799.03万元,近五日累计净流出5423.98万元。 风险提示:投资有风险,入市需谨慎。 ...
易瑞生物股价上涨6.43% 公司更换持续督导保荐代表人
Jin Rong Jie· 2025-08-15 17:54
公司最新公告显示,因原保荐代表人付书博工作调动,东兴证券委派林苏钦接任公司持续督导保荐代表 人职务,继续履行持续督导职责。 易瑞生物属于化学制药行业,公司主营业务为体外诊断产品的研发、生产和销售。公司产品涵盖传染病 检测、毒品检测、食品安全检测等多个领域。 风险提示:股市有风险,投资需谨慎。 易瑞生物最新股价为13.08元,较前一交易日上涨6.43%。当日开盘价为12.30元,最高触及13.26元,最 低下探12.26元,成交量为17.46万手,成交金额达2.25亿元。 资金流向方面,易瑞生物当日主力资金净流出49.03万元,近五个交易日累计净流出3471.28万元。 ...
迈瑞医疗股价微涨0.93% 将亮相服贸会健康卫生专题展
Sou Hu Cai Jing· 2025-08-13 16:50
Company Overview - Mindray Medical's latest stock price is 236.49 CNY, an increase of 2.19 CNY from the previous trading day [1] - The opening price for the day was 234.50 CNY, with a high of 236.70 CNY and a low of 232.53 CNY [1] - The trading volume was 73,986 hands, with a total transaction amount of 1.738 billion CNY [1] Industry Participation - Mindray Medical will participate in the 2025 China International Fair for Trade in Services, focusing on health and hygiene services from September 10 to 14 [1] - The theme of the exhibition is "Innovation, Intelligence, Development, and Benefit to the People" [1] - Mindray Medical will showcase its latest achievements alongside international companies such as GE Healthcare and Siemens Healthineers [1] Financial Flow - On the day of the report, the net outflow of main funds for Mindray Medical was 9.7791 million CNY [1] - Over the past five trading days, the cumulative net inflow was 265 million CNY [1]
北京热景生物技术股份有限公司关于公司及子公司近期获得资质情况的自愿披露公告
Shang Hai Zheng Quan Bao· 2025-08-11 19:32
证券代码:688068 证券简称:热景生物 公告编号:2025-056 北京热景生物技术股份有限公司 二、对公司的影响 上述资质的取得,丰富了公司产品的种类,进一步完善了公司体外诊断产品的菜单,完善了公司知识产 权保护体系,同时积极响应了海外市场的需求,便于进一步提高公司的市场拓展能力,提升公司核心竞 争力。 关于公司及子公司近期获得资质情况的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性依法承担法律责任。 北京热景生物技术股份有限公司(以下简称"公司")及子公司近期获得境外资质认证25项、授权专利2 件。相关信息如下: 一、获得资质的具体情况 (一)获得境外认证情况 ■■■ (二)获得授权专利情况 ■ 三、风险提示 上述产品的实际销售情况取决于市场的推广效果、同类竞争产品的销售以及产品需求等多重因素影响, 具有较大的不确定性。敬请广大投资者注意投资风险。公司将继续加大对产品的研发投入,不断向市场 推出对人类健康和生命有显著价值的产品,全力以赴做好公司经营。 特此公告。 北京热景生物技术股份有限公司董事会 2025年8月12日 ...
塞力医疗股价震荡上行 盘中波动超2%
Sou Hu Cai Jing· 2025-08-08 15:31
Company Overview - As of August 8, 2025, the stock price of Sely Medical is reported at 27.60 yuan, reflecting an increase of 0.73% from the previous trading day [1] - The company operates in the pharmaceutical commercial sector, focusing on medical testing centralized services and the research, production, and sales of in vitro diagnostic products [1] - Sely Medical's product range includes biochemistry, immunology, and molecular diagnostics, with business operations extending across multiple regions, including Hubei [1] Stock Performance - During the trading session on August 8, Sely Medical's stock exhibited significant volatility, with a morning rebound at 9:35 AM leading to a rise of over 2% within five minutes, followed by a quick pullback at 9:44 AM with a drop exceeding 2% [1] - The stock's opening price was 27.11 yuan, reaching a high of 28.40 yuan and a low of 26.20 yuan, resulting in a trading range of 8.03% [1] - The total trading volume for the day amounted to 9.85 billion yuan [1] Capital Flow - On August 8, the net inflow of main funds was 33.17 million yuan, accounting for 0.63% of the circulating market value [1] - However, over the past five trading days, the overall trend for main funds has shown a net outflow of 456 million yuan, which represents 8.65% of the circulating market value [1]
亚辉龙股价小幅回落 欧洲收入占比不足10%
Jin Rong Jie· 2025-08-07 18:41
Group 1 - The company's stock price on August 7 was 15.81 yuan, down 0.94% from the previous trading day, with a trading volume of 92,949 lots and a transaction amount of 148 million yuan [1] - The company specializes in the research, production, and sales of in vitro diagnostic products, covering areas such as autoimmune, infectious immunity, reproductive health, and diabetes monitoring, with operations in over 120 countries and regions globally [1] - Recent data indicates that the revenue from the European region accounts for less than 10% of the company's total overseas revenue, with the company stating its overseas business spans the Americas, Europe, Asia, and Africa [1] Group 2 - On the same day, the net outflow of main funds was 6.023 million yuan, with a cumulative net outflow of 8.0801 million yuan over the past five days [2]
迈瑞医疗全球第二总部在汉开园,300%增资“追投”武汉
Chang Jiang Ri Bao· 2025-08-06 00:28
Group 1 - The core investment of 4.5 billion yuan in the establishment of Mindray Medical's second global headquarters in Wuhan aims to accelerate the development of a biomedicine and medical device industry cluster in the region [1][2] - The Wuhan base covers an area of 110 acres and includes a research and development base and a production base, featuring approximately 13,000 square meters of specialized laboratory space and over 90 laboratories [1] - The production base will focus on high-end manufacturing of orthopedic materials, minimally invasive surgical instruments, and biological raw materials, leveraging digital construction [1] Group 2 - Mindray Medical's senior vice president stated that the Wuhan base will serve as a "cultivation dish" for the company's second growth curve, encompassing the entire value chain from R&D to manufacturing and customer training [2] - The base plans to recruit 2,000 employees within five years, with 60% of them being R&D talents, supported by local talent policies to create a "Silicon Valley-like" ecosystem [2] - The establishment of the base is expected to attract over 100 supporting enterprises, further enhancing the high-end medical equipment industry cluster in Wuhan [2] Group 3 - Mindray Medical is recognized as China's largest and a global leader in the medical device sector, with products spanning life information and support, in vitro diagnostics, and medical imaging, distributed in over 190 countries and regions [2] - The registered capital of Mindray's wholly-owned subsidiary in Wuhan increased from 500 million yuan to 2 billion yuan in June, marking a 300% increase [2] - The president of Mindray emphasized that Wuhan is not only a crucial talent supply base but also a core component of the company's long-term strategy [2]
塞力医疗股价震荡下行 盘中快速反弹与回调交替出现
Sou Hu Cai Jing· 2025-08-05 14:37
Core Viewpoint - The stock price of Saily Medical closed at 29.50 yuan on August 5, showing a decline of 0.51% compared to the previous trading day, with notable price fluctuations throughout the day [1] Company Overview - Saily Medical's main business includes centralized marketing and service for medical testing, as well as the agency, research, production, and sales of in vitro diagnostic products [1] - The company holds a significant market influence in the medical commercial sector within Hubei province [1] Market Activity - On August 5, the net outflow of main funds was 4.6852 million yuan, with a cumulative net outflow of 276 million yuan over the past five trading days [1] - The trading volume for the day reached 1.055 billion yuan, with a turnover rate of 18.99%, indicating a high level of market activity [1]